Adocia SA (EPA: ADOC) is a French clinical-stage biotechnology company focused on innovative formulations for diabetes and metabolic diseases. Using its proprietary BioChaperone platform, Adocia aims to improve the performance of insulin and other injectable therapies. Its stock tends to move on clinical trial outcomes, partnership announcements, and progress in advancing its pipeline toward commercialization.